Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study

Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Taiyo Otoshi, Kosuke Hamada, Takeshi Yamasaki, Tatsuya Nakatani

Citation	International Journal of Clinical Oncology, 24(7); pp 848–856
Published	2019-02-11
Type	Journal Article
Textversion	Author
Rights	This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: https://doi.org/10.1007/s10147-019-01413-1 . See Springer Nature terms of use. https://www.springer.com/gp/open-access/publication-policies/aam-terms-of-use .
DOI	10.1007/s10147-019-01413-1

Self-Archiving by Author(s)
Placed on: Osaka City University

IGUCHI, T., TAMADA, S., KATO, M., YASUDA, S., OTOSHI, T., HAMADA, K., YAMASAKI, T., & NAKATANI, T. (2019). Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study. *International Journal of Clinical Oncology*. 24, 848-856. DOI:10.1007/s10147-019-01413-1

**Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen
blockade therapy with bicalutamide: A retrospective study**

Authors

Taro Iguchi: taro@msic.med.osaka-cu.ac.jp

Satoshi Tamada: s-tamada@med.osaka-cu.ac.jp

Minoru Kato: m1112173@med.osaka-cu.ac.jp

Sayaka Yasuda: yasudas@med.osaka-cu.ac.j

Taiyo Otsoshi: sun.otoshi@gmail.com

Kosuke Hamada: hamakousanself@gmail.com

Takeshi Yamasaki: tysy-y@mx5.canvas.ne.jp

Tatsuya Nakatani: nakatani@med.osaka-cu.ac.jp

Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan

1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

Phone: +81-6-6645-3857

Fax: +81-6-6647-4426

Corresponding author: Taro Iguchi

Abstract

Background: Alternative anti-androgen therapy (AAT) with flutamide after combined androgen blockade (CAB) therapy with bicalutamide for metastatic prostate cancer is common. However, no studies have compared enzalutamide without AAT with enzalutamide after AAT with flutamide as treatment for castration-resistant prostate cancer (CRPC). We aimed to compare the efficacies of flutamide and enzalutamide for CRPC.

Methods: In our hospital, 55 patients were diagnosed with CRPC after CAB therapy and administered flutamide or enzalutamide between May 2014 and December 2017. Patients with flutamide failure were administered enzalutamide. We evaluated the prostate-specific antigen (PSA) best response with initial therapy, 2) PSA progression-free survival with initial therapy (PSA-PFS), 3) PSA best response with enzalutamide therapy, 4) PSA-PFS of enzalutamide therapy, and 5) overall survival (OS).

Results: As first-line therapy, patients were administered enzalutamide (n = 29) or flutamide (n = 26). In the flutamide group, 18 patients showed disease progression and were administered enzalutamide. PSA best response was statistically higher in the enzalutamide group. PSA-PFS was significantly longer in the enzalutamide group (hazard ratio (HR) 0.42, 95% confidence interval (CI) 0.19–0.92, p = 0.024). However, there was no significant difference in PSA best response with enzalutamide therapy and PSA-PFS between the first- and second-line enzalutamide therapies (HR 0.80, 95% CI 0.33–1.94, p = 0.62). There was no

significant difference in OS between enzalutamide and flutamide groups (HR1.85, 95% CI 0.53–6.42, $p = 0.33$).

Conclusions: AAT with subsequent flutamide after CAB therapy with bicalutamide may be suitable for some CRPC patients.

Keywords: Castration-resistant prostate cancer, Enzalutamide, Flutamide

Introduction

Prostate cancer is the most commonly diagnosed cancer and is the third leading cause of cancer-related deaths among men worldwide [1]. In most patients who are treated for advanced recurrent prostate cancer with androgen-deprivation therapy (ADT) that comprises a luteinizing hormone-releasing hormone (LHRH) analog or orchiectomy, with or without an anti-androgen, disease progression occurs despite effective suppression of serum testosterone. These patients are then diagnosed with castration-resistant prostate cancer (CRPC).

In Asia, including Japan, combined androgen blockade (CAB) therapy using an LHRH analog with an anti-androgen is more widely used than LHRH analog monotherapy, because CAB therapy is reported to be superior to ADT without an anti-androgen in terms of long-term efficacy among Japanese patients with prostate cancer [2]. Therefore, the majority of Japanese patients with advanced prostate cancer are treated with CAB and are diagnosed with CRPC by prostate-specific antigen (PSA) recurrence with or without confirming anti-androgen withdrawal syndrome (AWS). Alternative anti-androgen therapy (AAT) with flutamide, subsequent to CAB therapy with bicalutamide, was widely used before the androgen receptor-targeted therapy (ART) era, particularly in Japan [3-8]. The response rate of AAT, defined as a decrease of >50% from the baseline serum PSA level, was 22%, and patients who respond to AAT have been reported

1 to have good prognosis [4]. This phenomenon is attributed to the different mechanism of actions among
2
3
4 anti-androgens [7]. Indeed, we have experienced long-lasting effective cases by AAT in clinical practice.
5
6
7

8
9 Flutamide, a non-steroidal oral anti-androgen, was often used in clinical practice before bicalutamide was
10
11
12 approved. Some small, single-arm non-randomized studies suggest a PSA benefit when flutamide is used as
13
14
15 second-line hormonal therapy [3-9]. However, the use of flutamide is optional for limited patients with
16
17
18 CRPC according to the American Urological Association guidelines [10] owing to the modest PSA benefit,
19
20
21 with PSA decline of >50% occurring typically in only 20%–40% of men with a median duration measured
22
23
24 in several months.
25
26
27

28
29 Enzalutamide is an androgen receptor inhibitor that targets several steps in the androgen receptor signaling
30
31
32 pathway. It inhibits the binding of androgens to the androgen receptor, androgen-receptor nuclear
33
34
35 translocation, and androgen receptor-mediated DNA binding [11]. In preclinical studies, enzalutamide
36
37
38 showed a higher affinity for the androgen receptor and superior suppression of key components of the
39
40
41 androgen receptor signaling pathway than bicalutamide [11,12]. Subsequently, enzalutamide was approved
42
43
44 for the treatment of metastatic CRPC based on the results of two pivotal placebo-controlled phase III trials,
45
46
47
48
49 namely, AFFIRM [13] and PREVAIL [14].
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Before the ART era, the treatment options for CRPC were limited, and AAT with flutamide has been widely used in Asia, including Japan. According to the post hoc analyses of the PREVAIL study, 40% of east Asian patients (50% of Japanese patients) were administered 2 prior anti-androgen drugs, which are bicalutamide and flutamide [15,16]. However, no clinical studies have compared enzalutamide without AAT (early group) with enzalutamide after AAT with flutamide (deferred group) as treatment modalities for CRPC. Moreover, there is no evidence of the superiority of enzalutamide to AAT in terms of efficacy, and the comparison between enzalutamide and enzalutamide after AAT would be meaningful. Thus, we aimed to compare enzalutamide without AAT with enzalutamide after AAT with flutamide for CRPC after CAB therapy with bicalutamide.

Materials and Methods

Study population

Records of 94 CRPC patients treated in Osaka City University Hospital, Osaka, Japan, between May 2014 and December 2017 were reviewed. All the patients were histologically diagnosed as having prostate cancer and underwent CAB therapy with 80-mg bicalutamide and luteinizing hormone-releasing hormone agonist/antagonist as initial hormonal therapy. They were also diagnosed with CRPC on the basis of biochemical or radiographic progression with serum testosterone level <50 ng/dL despite undergoing CAB therapy. A total of 55 CRPC patients met the eligibility criterion of no prior treatment with enzalutamide, flutamide, abiraterone, or chemotherapy after CAB therapy.

Treatment

The patients were treated with enzalutamide (160 mg/day, 4 × 40 mg capsules once daily) or flutamide (375 mg/day; 3 × 125 mg tablets thrice daily) depending on the patients' preference and doctor's decision. The dose of the treatment drug can be reduced according to the adverse effects (enzalutamide: 120 mg/day, flutamide: 250 mg/day). The treatment was changed in case of intolerable adverse effects, which may result in difficulty in continuing the medication, or disease progression, defined as PSA progression, radiographic progression, or worsening of symptoms. The flutamide treatment was changed if the patient had PSA

1 progression, and enzalutamide was the primary drug for the subsequent treatment of patients treated with
2
3
4 flutamide.
5
6
7

8 ***Evaluation***

9

10
11 Patients were evaluated on the basis of the following outcomes:
12
13

- 14
15 1) *PSA response rate at 3 and 6 months*: PSA response was defined as PSA decrease of $\geq 50\%$ from the
16
17 baseline. If the initial enzalutamide therapy was switched to other treatments due to disease progression
18
19 before 3 or 6 months, such cases were regarded as “non-responders”, regardless of the efficacy of the
20
21 subsequent treatment. In addition, the PSA response rate in patients in whom flutamide was switched
22
23 to enzalutamide was calculated to determine the efficacy of enzalutamide in the flutamide-to-
24
25 enzalutamide cohort.
26
27
28
29
30
31
32
33
34
35
- 36 2) *PSA best response*: PSA best response was defined as the maximum PSA decreased rate from baseline.
37
38
39
- 40 3) *PSA progression-free survival*: PSA progression-free survival (PSA-PFS) of enzalutamide or flutamide
41
42 was calculated.
43
44
45
46
- 47 4) *Time to treatment failure with initial therapy*: Time to treatment failure with initial therapy (TTF) was
48
49 defined as the time from the start of initial therapy to treatment failure of initial therapy.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 5) *PSA progression-free survival of enzalutamide therapy*: PSA progression-free survival of enzalutamide
2
3
4 therapy (PSA-PFS-Enz) was defined as PSA-PFS of the first-line enzalutamide therapy or second-line
5
6
7 enzalutamide therapy, as the subsequent treatment of flutamide.
8
9
- 10 6) *Time to treatment failure with enzalutamide*: Time to treatment failure with enzalutamide (TTF-Enz)
11
12 was defined as the time from the start of initial therapy to treatment failure with enzalutamide. If the
13
14
15 initial flutamide therapy was continued, the patients were considered to have not failed the treatment
16
17
18
19 initial flutamide therapy was continued, the patients were considered to have not failed the treatment
20
21
22 with enzalutamide.
23
24
- 25 7) *Overall survival*: Deaths from any cause comprise the overall survival (OS) events.
26
27
28
- 29 8) *Subsequent Life-prolonging Therapy*: Information regarding initiation of subsequent prostate cancer
30
31
32 therapies was collected.
33
34
35
- 36 9) *Safety*: Information on all the adverse effects due to the treatment drug was collected.
37
38
39

40 All clinical assessments of disease progression were defined according to the Prostate Cancer Clinical
41
42
43 Trials Working Group (PCWG2) criteria [17].
44
45
46

47 ***Ethical consideration***

48
49

50 This study was approved by the Institutional Review Board of Osaka City University Hospital
51
52
53
54 (Reference number: 3109). Given that this study was an observational study, we did not obtain consent
55
56
57 directly from the patients, but did guarantee the opportunity by opt-out.
58
59
60
61
62
63
64
65

1 *Statistical analysis*
2
3

4 Differences in categorical parameters were assessed using the Student's t-test. Cumulative rates were
5
6
7
8 estimated using the Kaplan–Meier method, and the significance of differences between curves was tested
9
10
11
12 by the log-rank test. A value of $P < 0.05$ was considered statistically significant. All data were analyzed
13
14
15 using Prism 7 (GraphPad Software, La Jolla, CA).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results

Patients' characteristics

All of the 55 patients in this study were treated with bicalutamide as CAB therapy before the diagnosis of CRPC. For the first-line therapy of CRPC, 29 patients were treated with enzalutamide, whereas 26 patients were treated with flutamide. Among these patients, baseline demographic and disease characteristics were not significantly different between the enzalutamide and flutamide treatment groups (Table 1). Of the 26 patients treated with flutamide, 18 patients were confirmed to have disease progression and were treated with enzalutamide as a subsequent therapy.

Regarding the patients' characteristics, our cohort had lower body weight and body mass index and higher percentage of ECOG performance status (PS) of 0 than the PREVAIL cohort. In terms of disease characteristics, our cohort had lower median PSA level at baseline, had Gleason score of 8 or higher, and had fewer prior radical prostatectomy or radiation therapy than the PREVAIL cohort, and we included the patients without metastases (15%). These characteristics are common in Japanese CRPC patients in clinical practice.

PSA response rate at 3 and 6 months

Of the 29 patients treated with enzalutamide as first-line therapy, 25 and 23 patients had PSA response, indicating that PSA decreased by $\geq 50\%$ from baseline at 3 and 6 months, respectively. In contrast, of the 26

1 patients treated with flutamide, 8 and 1 patient had PSA response at 3 and 6 months, respectively (Table 2).

2
3
4 However, 14 and 11 patients who underwent second-line enzalutamide therapy after flutamide had PSA
5
6
7
8 response at 3 and 6 months, respectively. The PSA response of the first-line therapy at 3 and 6 months were
9
10
11 statistically higher in the patients treated with enzalutamide, but there was no significant difference in the
12
13
14
15 PSA response of enzalutamide therapy between the first- and second-line therapies (Table 3).

16 ***PSA best response***

17
18
19 Of the 29 patients who underwent first-line enzalutamide therapy, 25 patients had $\geq 50\%$ PSA response at
20
21
22 their PSA best response, whereas 12 in the 26 patients treated with flutamide had $\geq 50\%$ PSA response at
23
24
25
26 their PSA best response. The PSA best response was statistically higher in the patients treated with
27
28
29 their PSA best response. The PSA best response was statistically higher in the patients treated with
30
31
32 enzalutamide (Fig. 1a). However, there was no difference in the PSA best response between the first- and
33
34
35
36 second-line enzalutamide therapies (Fig. 1b).

37 ***PSA-PFS***

38
39
40 PSA-PFS of the first-line therapy in the enzalutamide treatment group was significantly longer than that in
41
42
43 the flutamide treatment group (median, 21.2 and 8.6 months, respectively; HR: 0.42, 95% CI, 0.19-0.92,
44
45
46
47
48
49
50
51 p=0.024) (Fig. 2a).

52 ***Time to treatment failure with initial therapy (TTF)***

TTF in the enzalutamide treatment group was significantly longer than that in the flutamide treatment group (median, 22.6 and 8.4 months, respectively; HR: 0.39, 95% CI, 0.19-0.82, p=0.009) (Fig. 2b).

PSA progression-free survival of enzalutamide therapy (PSA-PFS-Enz)

There was no significant difference in PSA-PFS-Enz between the first-and second-line therapies following flutamide (median, 21.2 and 14.9 months, respectively; HR: 0.80, 95% CI, 0.33-1.94, p=0.62) (Fig. 3A).

Time to treatment failure with enzalutamide (TTF-Enz)

There was no significant difference in TTF-Enz between the first line enzalutamide therapy and sequential therapy of flutamide to enzalutamide (median, 22.6 and 35.4 months, respectively; HR: 1.46, 95% CI, 0.62-3.47, p=0.38) (Fig. 3B).

OS

There was no significant difference in OS between the first-line enzalutamide therapy and sequential therapy of flutamide to enzalutamide (median, not reached in both groups, HR: 1.85, 95% CI, 0.53-6.42, p=0.33) (Fig. 4).

Subsequent life-prolonging therapy

At the data cut, 17 of the 29 patients in the enzalutamide group continued taking enzalutamide and 8 of the 26 patients in the flutamide group continued taking flutamide. All the patients who had progression with

1 flutamide were administered enzalutamide as second-line therapy. Those who had progression with
2
3
4 enzalutamide were administered abiraterone, docetaxel, cabazitaxel radium-223, and other hormonal drugs
5
6
7
8 (Table 4). There was no significant difference in the subsequent life-prolonging therapy between the two
9
10
11 groups.
12

13 ***Safety***

14
15 Adverse events are summarized in Table 5. Flutamide had a favorable safety profile as described in a
16
17
18
19 previous report [18] and flutamide was discontinued for 2 patients because of appetite loss and diarrhea.
20
21
22

23
24 Enzalutamide also had a favorable safety profile similar to that in the PREVAIL study in which
25
26
27
28
29 enzalutamide was discontinued for 2 patients because of appetite loss and taste disorder [14]. Of 47 patients
30
31
32
33 treated using first-line or second-line enzalutamide, the enzalutamide dose was reduced to 120 mg/day in 26
34
35
36
37 patients because of adverse effects; however, all the adverse effects ameliorated or disappeared after dose
38
39
40 reduction.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

In Asia, including Japan, CAB therapy is widely used than the LHRH analog monotherapy among Japanese patients with prostate cancer, because CAB therapy is reported to be superior to ADT without an anti-androgen in terms of long-term efficacy [2]. The majority of Japanese patients with advanced prostate cancer are treated with CAB therapy and AAT with flutamide as the subsequent therapy for CRPC was widely used before the ART era [3-8]. After launching enzalutamide and abiraterone in 2014, ART became the first choice of treatment for CRPC instead of AAT with flutamide, but flutamide is still used widely in clinical practice because of previous experiences and economic benefits. Even after the ART era, it was reported that the duration of the initial CAB therapy was significantly correlated with PSA decline of AAT therapy [9,19]. However, there is no evidence of the superiority of enzalutamide to AAT, and no clinical studies have compared enzalutamide without AAT with enzalutamide after AAT with flutamide as treatment modalities for CRPC.

We investigated the efficacy of enzalutamide and flutamide as first-line therapies for CRPC. In this study, enzalutamide was superior to flutamide in terms of PSA response rate at 3 and 6 months, PSA best response, PSA-PFS, and TTF as the first-line therapy for CRPC after CAB therapy with bicalutamide. As reported in STRIVE and TERRAIN studies that enzalutamide was superior to bicalutamide as the first-line

1 therapy for CRPC after ADT, enzalutamide is revealed to be superior to old anti-androgens in clinical
2
3
4 practice [20,21].
5
6
7

8
9 We also investigated the efficiency of enzalutamide between the early and deferred groups. The
10
11
12 efficiency of enzalutamide was not changed in terms of PSA-PFS and TTF, regardless of flutamide use as
13
14
15
16 shown in Fig. 3a and 3b. Furthermore, there was no difference in the OS after CRPC regardless of
17
18
19 flutamide use.
20
21
22
23

24 From the result of this study, flutamide was demonstrated to be inferior to enzalutamide as first-line
25
26
27 therapy for CRPC after CAB therapy; however, 46% of patients treated with flutamide had PSA response,
28
29
30 indicating a decrease in PSA by $\geq 50\%$ from baseline at 3 months, and 61.5% of patients had PSA decline
31
32
33 from baseline. Moreover, the median PSA-PFS was 8.6 months. The previous studies on flutamide as AAT
34
35
36 revealed that the responders, whose PSA decline was $>50\%$ from baseline, had better prognosis and
37
38
39 achieved sufficient benefits from flutamide [4,5,7,8]. PSA nadir and duration of sensitivity to CAB therapy
40
41
42 are predictors of the AAT response [9,22]. Responders to flutamide in this study had statistically lower PSA
43
44
45 nadir and longer time to PSA nadir at CAB therapy than did non-responders. Similarly, responders to
46
47
48 enzalutamide had the same characteristics (data not shown).
49
50
51
52
53

54
55
56 In this study, enzalutamide was equally effective for the responders to flutamide, similar to the patients
57
58
59 who were treated directly with enzalutamide. Even if the flutamide did not work for some of the patients,
60
61
62
63
64
65

1 the disadvantage might be kept to a minimum by early administration of enzalutamide. The adverse effects
2
3
4 of flutamide observed in this study include a small number of cases with diarrhea and liver dysfunction,
5
6
7
8 which was similar to the adverse effects found in a previous report [18]. On the other hand, patients treated
9
10
11 with enzalutamide had some adverse effects, such as fatigue and appetite loss, which were similar to those
12
13
14 previously reported [14]. In this study, only 2 patients discontinued enzalutamide due to adverse effects,
15
16
17
18 which could be attributed to the fact that we used the original questionnaire of adverse effects as patient-
19
20
21 reported outcomes, and we noted the adverse effects early and could intervene by reducing the treatment
22
23
24
25 dose (160 to 120 mg/day). In terms of cost, flutamide is cheaper than enzalutamide (\$185 vs \$2456 in
26
27
28 Japan) and flutamide may be effective for more than two years in some patients; thus, there is a \$54500
29
30
31 difference in medical expenses between the two therapies.
32
33
34
35

36 Recently, some studies have reported the effect of abiraterone use, which was not change to flutamide,
37
38
39 for CRPC patients after CAB therapy [23,24]. For enzalutamide, similar results are suggested in this study,
40
41
42
43 which indicate that ART, such as enzalutamide and abiraterone, does not have cross-resistance with the
44
45
46 first-generation anti-androgen, and flutamide may not shorten the OS of CRPC patients. Currently, the first-
47
48
49 generation anti-androgens, such as bicalutamide and flutamide, are not recommended in the CRPC
50
51
52
53 guidelines, but treatment options should be taken into consideration and need to be verified in a prospective
54
55
56
57 study because of their low cost and low incidence of adverse effects.
58
59
60
61
62
63
64
65

1 Current treatment trend of prostate cancer is upfront treatment by strong agents. Docetaxel and
2
3
4 abiraterone are now available as standard drugs for metastatic hormone sensitive prostate cancer according
5
6
7
8 to the result of CHARTTED, STAMPEDE, and LATITUDE studies [25-27]. Moreover, enzalutamide was
9
10
11 more effective than bicalutamide in men with CRPC after ADT [20,21]. However, in all of these trials,
12
13
14 there were some patients who were not treated according to the current standard of treatment (e.g. in
15
16
17 LATITUDE study, ART drugs were used as subsequent life-prolonging therapy in only 27% of patients in
18
19
20 the placebo group after disease progression), and they did not compare the early group with the deferred
21
22
23 group. As in this study, the long-term effect may not be significant despite the positive proximity effect
24
25
26 because of the deferred administration of standard drugs and it seems to be significant for comparison,
27
28
29 including subsequent life-prolonging therapy. According to the findings of this study, it is important to
30
31
32 investigate who among the patients will benefit the most with flutamide before enzalutamide. Flutamide
33
34
35 may have therapeutic and economic potential for some CRPC patients who had lower PSA nadir and longer
36
37
38 time to PSA nadir at CAB therapy.
39
40
41
42
43
44
45
46

47 There are some limitations in this study. This is a small-sized, retrospective study conducted at a single
48
49
50 center. Given that the drug selection was dependent on the doctors and patients, a selection bias may have
51
52
53 existed. Moreover, the number of subjects was too small, and the observation periods were too short to
54
55
56 draw conclusions about the effect of AAT. Currently, two prospective clinical studies comparing
57
58
59
60
61
62
63
64
65

enzalutamide with flutamide for CRPC after CAB therapy are ongoing (NCT02346578 and NCT
02918968). We are expecting that the results of the prospective studies will confirm our findings.

Conclusions

Enzalutamide is significantly superior to flutamide as the first-line therapy for CRPC after CAB therapy with bicalutamide. However, AAT with flutamide may be suitable for some CRPC patients. Moreover, there was no difference in the OS after CRPC regardless of flutamide use, if enzalutamide was used as a subsequent therapy.

Acknowledgments

The authors wish to thank the following collaborators for help with patient care: Dr. Katsuyuki Kuratsukuri, Dr. Nobuyuki Kuwabara, and Dr. Tomoaki Iwai.

Conflict of interest

Taro Iguchi, Sayaka Yasuda, and Tatsuya Nakatani received a research grant from Astellas Pharma Inc. and Bayer Yakuhin, Ltd.; Taro Iguchi received lecture fees from Astellas Pharma Inc., Bayer Yakuhin, Ltd. Janssen Pharmaceutical K.K., and Sanofi K.K.; Satoshi Tamada, Minoru Kato, Taiyo Otoshi, Kosuke Hamada, and Takeshi Yamasaki have no conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. *CA Cancer J Clin* 68 (1):7-30. doi:10.3322/caac.21442
2. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate C (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. *Cancer* 115 (15):3437-3445. doi:10.1002/cncr.24395
3. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H (2000) Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. *European urology* 37 (2):218-222. doi:10.1159/000020121
4. Miyake H, Hara I, Eto H (2005) Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. *BJU Int* 96 (6):791-795. doi:10.1111/j.1464-410X.2005.05766.x
5. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T (2007) Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. *Int J Urol* 14 (2):128-132. doi:10.1111/j.1442-2042.2007.01698.x
6. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y (2007) Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer. *Int J Urol* 14 (3):264-267. doi:10.1111/j.1442-2042.2007.01681.x
7. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study G (2008) Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. *The Journal of urology* 180 (3):921-927. doi:10.1016/j.juro.2008.05.045
8. Okegawa T, Nutahara K, Higashihara E (2010) Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. *Int J Urol* 17 (11):950-955. doi:10.1111/j.1442-2042.2010.02620.x
9. Yasui M, Uemura K, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Inoue M, Ohta JI, Yokomizo Y, Yao M, Uemura H, Miyoshi Y (2016) Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer. *Japanese journal of clinical oncology* 46 (11):1042-1046. doi:10.1093/jjco/hyw110

10. Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. *The Journal of urology* 195 (5):1444-1452. doi:10.1016/j.juro.2015.10.086
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science (New York, NY)* 324 (5928):787-790. doi:10.1126/science.1168175
12. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J (2010) Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). *Journal of medicinal chemistry* 53 (7):2779-2796. doi:10.1021/jm901488g
13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. *The New England journal of medicine* 367 (13):1187-1197. doi:10.1056/NEJMoa1207506
14. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. *The New England journal of medicine* 371 (5):424-433. doi:10.1056/NEJMoa1405095
15. Kim CS, Choi YD, Lee SE, Lee HM, Ueda T, Yonese J, Fukagai T, Chiong E, Lau W, Abhyankar S, Theeuwes A, Tombal B, Beer TM, Kimura G (2017) Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer. *Medicine* 96 (27):e7223. doi:10.1097/md.00000000000007223
16. Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T (2016) Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. *Int J Urol* 23 (5):395-403. doi:10.1111/iju.13072
17. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G

- (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 26 (7):1148-1159. doi:10.1200/JCO.2007.12.4487
18. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Jr., Bueschen AJ, Lowe BA (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. *The New England journal of medicine* 339 (15):1036-1042. doi:10.1056/nejm199810083391504
19. Momozono H, Miyake H, Tei H, Harada KI, Fujisawa M (2016) Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. *Molecular and clinical oncology* 4 (5):839-844. doi:10.3892/mco.2016.817
20. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016) Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 34 (18):2098-2106. doi:10.1200/jco.2015.64.9285
21. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A (2016) Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. *The Lancet Oncology* 17 (2):153-163. doi:10.1016/s1470-2045(15)00518-5
22. Kamiya N, Suzuki H, Nishimura K, Fujii M, Okegawa T, Matsuda T, Morita T, Takihana Y, Ozono S, Namiki M, Matsubara A, Ichikawa T, Miki T (2014) Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. *Japanese journal of clinical oncology* 44 (3):263-269. doi:10.1093/jjco/hyt230
23. Nagai T, Naiki T, Iida K, Etani T, Ando R, Hamamoto S, Sugiyama Y, Akita H, Kubota H, Hashimoto Y, Kawai N, Yasui T (2018) Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade. *Prostate international* 6 (1):18-23. doi:10.1016/j.pnil.2017.07.001
24. Zhao JG, Liu JD, Shen PF, Tang X, Sun GX, Zhang XM, Chen JR, Shu KP, Shi M, Zeng H (2018) Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant

prostate cancer: a real-world retrospective study. Asian journal of andrology 20 (6):545-550.

doi:10.4103/aja.aja_58_18

25. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. The New England journal of medicine 377 (4):352-360. doi:10.1056/NEJMoa1704174
26. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine 377 (4):338-351. doi:10.1056/NEJMoa1702900
27. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine 373 (8):737-746. doi:10.1056/NEJMoa1503747

Table 1

Baseline patient and disease characteristics

	Enzalutamide	Flutamide	p value
	(n = 29)	(n = 26)	
Median age (years)	75 (53-91)	78 (63-92)	0.13
Median body weight (kg)	62 (49-97)	63 (36-78)	
Median body mass index (kg/m ²)	23 (20-31)	23 (13-30)	
Initial PSA (ng/mL)	249 (8.8-8835)	68 (6.7-3254)	0.09
Duration of CAB therapy	22.9 (6.9-92.2)	31.5 (9.7-158)	0.18
PSA at first-line therapy for CRPC	8.9 (1.1-172)	3.2 (0.4-330)	0.61
Median observation period (months)	16.8 (3.0-48.9)	25.8 (5.8-52.9)	0.27
Gleason score ≥ 8 at initial diagnosis (%)	24 (83%)	24 (92%)	0.43
ECOG PS = 0 (%)	23 (79%)	19 (73%)	
ECOG PS ≥ 2 (%)	2 (7%)	1 (4%)	
Prior CAB therapies with bicalutamide (%)	29 (100%)	26 (100%)	
Prior radical prostatectomy (%)	0 (0%)	1 (4%)	
Prior radiation therapy (%)	5 (17%)	2 (8%)	0.43

nmCRPC	4 (14%)	4 (15%)	0.43
--------	---------	---------	------

PSA, prostate-specific antigen; CAB, combined androgen blockade; CRPC, castration-resistant prostate cancer; PS, performance status; nmCRPC, nonmetastatic castration-resistant prostate cancer

Table 2

PSA response rate at 3 and 6 months and PSA best response of each therapy

	First-line enzalutamide	First-line flutamide	
PSA response rate	(n=29)	(n=26)	p value
3 months	25 (86%)	8 (31%)	<0.01
6 months	23 (79%)	1 (4%)	<0.01
Best response	25 (86%)	12 (46%)	<0.01

PSA, prostate-specific antigen

Table 3

PSA response rate at 3 and 6 months and PSA best response of enzalutamide therapy

	First-line enzalutamide	Second-line enzalutamide	p value
PSA response rate at 3 months	25/29 (79%)	14/18 (78%)	0.69
PSA response rate at 6 months	18/23 (78%)	11/14 (79%)	1.00
PSA response rate (best response)	25/29 (79%)	17/18 (94%)	0.64

PSA, prostate-specific antigen

Table 4

Subsequent life-prolonging therapy after initial therapy

	Enzalutamide	Flutamide
	(n = 29)	(n = 26)
Ongoing initial therapy	17	8
Any subsequent life-prolonging therapy	12	18
Enzalutamide	0	18
Abiraterone	2	2
Docetaxel	5	4
Cabazitaxel	3	1
Radium-223	3	1
Others	7	4

Table 5

Adverse events and workaround

	First-line enzalutamide		First-line flutamide		Second-line enzalutamide	
	(n = 29)		(n = 26)		(n = 18)	
	All grades	Grade ≥ 3	All grades	Grade ≥ 3	All grades	Grade ≥ 3
Adverse effects	number of patients (percent)					
Fatigue	10 (34)	2 (7)			6 (33)	
Appetite loss	6 (21)		2 (8)	1 (4)	3 (17)	1 (6)
Nausea	5 (17)				3 (17)	
Hypertension	2 (7)					
Taste disorder	2 (7)				2 (11)	
Liver dysfunction			1 (4)		1 (6)	
Hyponatremia			1 (4)	1 (4)		
Diarrhea			1 (4)			
Others	1 (3)				2 (11)	
Workaround						
Dose reduction	14 (48)		2 (8)		12 (67)	
Interruption			1 (4)			
Discontinuation	1 (3)		2 (8)		1 (6)	

Figure legends

Fig. 1

PSA best response. (a) Enzalutamide and flutamide as first-line therapies for CRPC. (b) Enzalutamide as first- and second-line therapies after flutamide therapy. PSA = prostate-specific antigen; CRPC = castration-resistant prostate cancer

Fig. 2

(a) PSA-progression free survival of the first line therapy for CRPC. (b) Time to treatment failure with initial therapy for CRPC. PSA = prostate-specific antigen; CRPC = castration-resistant prostate cancer

Fig. 3

(a) PSA progression-free survival of the first- and second-line enzalutamide therapies. (b) Time to treatment failure with enzalutamide. PSA = prostate-specific antigen

Fig. 4

Overall survival between the first-line enzalutamide therapy and the sequential therapy of flutamide to enzalutamide.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

Fig. 1

a

b

Figure 2

Fig. 2

a

b

Figure 3

Fig. 3

a

b

Figure 4

Fig. 4

HR: 1.85, 95% CI, 0.53-6.42, p=0.33

Numbers at risk

Enz	29	18	11	7	4
Flu	26	22	15	4	2